Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ADXN vs PYPD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PYPD Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–1 Matrix Metrics)

PYPD Overall Winner 6-Pillar Tally: ADXN 1 – 4 PYPD (1 Tie) Matrix Metrics: ADXN 1 – 6 PYPD

As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Addex Therapeutics Ltd (ADXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ADXN carries a Unified Composite Score of 30.2/100 (SELL) at $3.57 (N/M Forward P/E, -3130.7% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.50 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both ADXN (30.2/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADXN vs PYPD
ADXN NASDAQ
Addex Therapeutics Ltd American Depositary Shares
Pharmaceutical Preparations
$3.57
-6.79% 1D
Market Cap $7.1M
TTM Revenue $83,069
Forward P/E N/M
Beta / 30D Vol 2.28β · 307% Vol
Unified Composite Score
30.2 / 100 SELL
Tech 3.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 54.7 · SMA20: $3.21 · SMA50: $3.21
PYPD NASDAQ Head-to-Head Winner
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.50
+5.63% 1D
Market Cap $132.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.88β · 59% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $5.81 · SMA50: $5.40

6-Pillar Scorecard Institutional Category Breakdown (ADXN 1 – 4 PYPD)

Columns: Metric · ADXN · PYPD
1. Valuation Multiples ADXN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 85.7x N/M
2. Growth & Scale PYPD
Revenue Growth (YoY) -72.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $83,069 N/A
Market Cap $7.1M $132.2M
3. Profitability & Quality PYPD
Gross Margin N/A N/A
Operating Margin -3130.7% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -150.6% -243.6%
4. Balance Sheet & Cash Flow PYPD
Cash Generation (TTM) -$2.6M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $2.18 Book/Sh · -150.6% ROE $5.0M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PYPD
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 106.3% (12th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADXN (1) vs PYPD (6)
Institutional Metric ADXN PYPD Criterion Row Edge
Market Capitalization
Scale
$7.1M $132.2M Larger Scale PYPD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-72.7% +0.0% Higher Growth PYPD
Operating Margin (TTM)
Profitability
-3130.7% 0.0% Higher Margin PYPD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-150.6% -243.6% Higher ROE ADXN
52-Week Range Position
Momentum
11% ($3–$12) 82% ($4–$7) Stronger Trend PYPD
Beta / 30D Volatility
Risk Regime
2.28β · 307% Vol 0.88β · 59% Vol Lower Realized Risk PYPD
Unified Institutional Score
Composite Signal
30.2 / 100 (SELL) 31.1 / 100 (SELL) Higher Composite PYPD
Trailing 12M Revenue (USD)
Operating Scale
$83,069 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 85.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.6M EBITDA ($2.18 Book/Sh · -150.6% ROE) N/A ($5.0M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PYPD +8.28 pp
ADXN: +29.35% · PYPD: +37.63%
3M Horizon PYPD +76.19 pp
ADXN: -40.0% · PYPD: +36.19%
6M Horizon PYPD +83.93 pp
ADXN: -46.88% · PYPD: +37.05%
1Y Horizon PYPD +138.8 pp
ADXN: -57.85% · PYPD: +80.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADXN vs PYPD. Trailing 12-month operating profitability (ADXN -3130.7% vs PYPD 0.0%) and valuation multiples (ADXN N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ADXN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$83,069
Gross MarginN/A
Op. Margin-3130.7%
ROE / Fwd P/E-150.6% · N/M
PYPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-243.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADXN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADXN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PYPD BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV 106.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PYPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADXN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1M market capitalization and -3130.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PYPD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ADXN vs PYPD Key Questions & Quantitative Answers

As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Addex Therapeutics Ltd (ADXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ADXN carries a Unified Composite Score of 30.2/100 (SELL) at $3.57 (N/M Forward P/E, -3130.7% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.50 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both ADXN (30.2/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

PYPD leads the Growth & Scale pillar: ADXN posts -72.7% YoY revenue growth and +0.0% YoY earnings growth on $83,069 TTM revenue (N/A gross margin, -3130.7% operating margin), compared with PYPD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ADXN generates $83,069 in USD-normalized revenue versus N/A for PYPD. In operating R&D and SG&A reinvestment, ADXN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PYPD.

ADXN screens cheaper on headline valuation multiples. ADXN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 85.7x EV/Revenue (unreported EBITDA margin), whereas PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADXN (-150.6% ROE) versus PYPD (-243.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ADXN carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.28β · 307% Vol realized risk). By comparison, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.88β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.